Immunological response after early extra and regular MMR immunization: 10 years follow-up
- Conditions
- Measles immunization in childrenInfections and Infestations
- Registration Number
- ISRCTN85713294
- Lead Sponsor
- ational Institute for Public Health and the Environment
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 88
Current inclusion criteria as of 30/01/2024:
1. Participation in the study on the immunological effects of early extra measles vaccination, as described in a separate study protocol (NL45616.094.13/IIV-273) or participation in the BMR-nul-study on epidemiological effects of early extra measles vaccination as described in a separate study protocol
2. The parents/legal representatives accept participation in the trial according to the described procedures
3. Presence of an informed consent signed by both parents/legal representatives
4. Children must have received the MMR-2 vaccination
Previous inclusion criteria:
1. Participation in the study on the immunological effects of early extra measles vaccination, as described in a separate study protocol (NL45616.094.13/IIV-273)
2. The parents/legal representatives accept participation in the trial according to the described procedures
3. Presence of an informed consent signed by both parents/legal representatives
4. Children must have received the MMR-2 vaccination
1. Presence of a serious disease that requires medical care that can interfere with the results of the study
2. Known or suspected immunological disorder
3. Bleeding disorders
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Measles-specific serum IgG measured by Luminex multiplex-based serology and virus-neutralizing antibodies by Plaque Reduction Neutralization Test (PRNT) 2 years (+/- 2 months) after MMR-2 vaccination
- Secondary Outcome Measures
Name Time Method Serum IgG antibody concentrations against mumps and rubella measured by Luminex multiplex-based serology 2 years (+/- 2 months) after MMR-2 vaccination